Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Single-center, Open-label, Single Dose, Two-period, Crossover Study to Investigate the Relative Bioavailability of Binimetinib 3 x15 mg and 45 mg Tablets in Healthy Participants

Next Previous
X
Search
Trial Profile

A Randomized, Single-center, Open-label, Single Dose, Two-period, Crossover Study to Investigate the Relative Bioavailability of Binimetinib 3 x15 mg and 45 mg Tablets in Healthy Participants

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Nov 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Binimetinib (Primary)
  • Indications Acute myeloid leukaemia; Biliary cancer; Breast cancer; Cancer; Chronic myeloid leukaemia; Colorectal cancer; Fallopian tube cancer; Gastrointestinal stromal tumours; Glioma; Haematological malignancies; Malignant melanoma; Multiple myeloma; Neurofibromatosis 1; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Rheumatoid arthritis; Solid tumours; Thyroid cancer; Uveal melanoma
  • Focus Pharmacokinetics
  • Sponsors Pierre Fabre

    • Most Recent Events

    • 11 Nov 2021 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top